vadacabtagene leraleucel (JCAR015) / Memorial Sloan-Kettering Cancer Center, BMS - LARVOL DELTA

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: May 2025 ➔ May 2026 | Trial primary completion date: May 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Leukemia • Oncology • Pediatrics • IKZF1 • KMT2A

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=17 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2025 ➔ Apr 2026 | Trial primary completion date: Apr 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov) - P1 | N=93 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2025 ➔ Jan 2026 | Trial primary completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: May 2024 ➔ May 2025 | Trial primary completion date: May 2024 ➔ May 2025

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Leukemia • Oncology • Pediatrics • IKZF1 • KMT2A

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=17 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2024 ➔ Apr 2025 | Trial primary completion date: Apr 2024 ➔ Apr 2025

Trial completion date • Trial primary completion date • Bone Marrow Transplantation • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov) - P1 | N=93 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2024 ➔ Jan 2025 | Trial primary completion date: Jan 2024 ➔ Jan 2025

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov) - P1/2 | N=50 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2023 ➔ Dec 2026 | Trial primary completion date: Dec 2023 ➔ Dec 2026

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=17 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2023 ➔ Apr 2024 | Trial primary completion date: Apr 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • Bone Marrow Transplantation • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD19

JCAR017 Is a Defined Composition CAR T Cell Product with Product and Process Controls That Deliver Precise Doses of CD4 and CD8 CAR T Cell to Patients with NHL (ASH 2017) - P1; "The process and product control of JCAR017 results in high T cell purity and low between-lot variance. Three aspects of JCAR017 manufacturing contribute to the low variability between lots and encouraging clinical profile: 1) a precise, consistent flat dose of administered CD4+ and CD8+ CAR T cells; 2) control and optimization of CD4 and CD8 T cell culture conditions that results in low variability of cytokine production (e.g. IL-2, TNFα and IFNγ, etc.); and 3) constant formulation and volume of drug product that contributes to consistent cell health."

CAR T-Cell Therapy • Biosimilar • Non-Hodgkin’s Lymphoma

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017 (ASH 2017) - P1; "Preliminary analysis has identified baseline patient characteristics, including inflammatory state and high tumor burden prior to treatment, as a means to identify patients at risk for increased toxicity following administration of JCAR017. Low tumor burden and low inflammatory state appear associated with improved toxicity profile and better durability of response. These preliminary data suggest that treating pts earlier in their course of therapy, or using a panel of clinical and laboratory biomarkers to risk stratify patients for potential early intervention, is feasible and may mitigate risk of toxicity and potentially improve durability of response."

Biomarker • CAR T-Cell Therapy • Clinical • Biosimilar • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Immunology • Indolent Lymphoma

Tumor gene signature associated with neurotoxicity in R/R B-ALL patients treated with JCAR015, a CD19-directed CAR T cell product. (ASCO 2018) - P1,P1/2,P2; "This exploratory analysis suggests that B-ALL subtypes differ in risk for CD19 CAR T associated NT with Ph-like patients being at significantly lower risk than non Ph-like patients. Risk stratification by molecular subtype or gene expression signature could play an important role in identifying patients at elevated risk for severe NT."

CAR T-Cell Therapy • Clinical • Gene Signature • Oncology

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov) - P1 | N=93 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2023 ➔ Jan 2024 | Trial primary completion date: Jan 2023 ➔ Jan 2024

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: May 2023 ➔ May 2024 | Trial primary completion date: May 2023 ➔ May 2024

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Leukemia • Oncology • Pediatrics • CD19 • IKZF1 • KMT2A

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov) - P1/2 | N=50 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

Long-Term Follow-up Study for Patients Previously Treated With JCAR015 (clinicaltrials.gov) - P=N/A | N=15 | Completed | Sponsor: Juno Therapeutics, a Subsidiary of Celgene | Active, not recruiting ➔ Completed | N=38 ➔ 15 | Trial completion date: Sep 2032 ➔ Oct 2021 | Trial primary completion date: Sep 2031 ➔ Oct 2021

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=17 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2022 ➔ Apr 2023 | Trial primary completion date: Apr 2022 ➔ Apr 2023

Trial completion date • Trial primary completion date • Bone Marrow Transplantation • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD19

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov) - P1 | N=93 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2022 ➔ Jan 2023 | Trial primary completion date: Jan 2022 ➔ Jan 2023

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: May 2022 ➔ May 2023 | Trial primary completion date: May 2022 ➔ May 2023

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Leukemia • Oncology • Pediatrics • CD19 • IKZF1 • KMT2A

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov) - P1/2; N=50; Active, not recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: Dec 2021 ➔ Dec 2022; Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1; N=23; Active, not recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: May 2021 ➔ May 2022; Trial primary completion date: May 2021 ➔ May 2022

Clinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Leukemia • Oncology • Pediatrics • CD19 • IKZF1 • KMT2A

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1; N=17; Active, not recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: Apr 2021 ➔ Apr 2022; Trial primary completion date: Apr 2021 ➔ Apr 2022

Trial completion date • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD19

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Memorial Sloan-Kettering Cancer Center

Clinical • New P1 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Leukemia • Oncology • Pediatrics • CD19 • IKZF1 • KMT2A

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1; N=23; Active, not recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: May 2018 ➔ May 2019; Trial primary completion date: May 2018 ➔ May 2019

Clinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • CD19 • IKZF1 • KMT2A

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1; N=23; Active, not recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: May 2020 ➔ May 2021; Trial primary completion date: May 2020 ➔ May 2021

Clinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • CD19 • IKZF1 • KMT2A

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1; N=23; Active, not recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: May 2019 ➔ May 2020; Trial primary completion date: May 2019 ➔ May 2020

Clinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • CD19 • IKZF1 • KMT2A